Amur Minerals complete the reverse takeover of Extruded Pharmaceuticals, change name to CRISM Pharmaceuticals and admission to AIM
May 2024
Prior to the acquisition Amur Minerals was a cash shell in accordance with Rule 15 of the AIM Rules.
Extruded Pharmaceuticals has developed ChemoSeed®, an implantable device designed to be implanted at the surgical margin of hard-to-treat cancers such as brain and pancreatic cancer as well as other solid tumours such as prostate, breast, bladder, lung and liver cancer.
ChemoSeed improves the clinical performance of new and currently available oncology drugs by delivering them directly to the tumour tissue/cancer cells, improving efficacy while reducing toxicity/side effects.
The first ChemoSeed is being developed for the localised treatment of brain tumours. This ChemoSeed has completed all preclinical testing, and they currently have a sterilised GLP batch available for biocompatibility testing before entering a Phase II registration quality clinical trial in Q4 of 2024.
Extruded Pharmaceuticals Ltd. has the capability to formulate any API into ChemoSeed and take it from formulation development through technology transfer, scale-up and GLP toxicity testing to clinical batch supply for clinical trials.
Reverse takeover of Extruded Pharmaceuticals, change name to CRISM Pharmaceuticals and admission to AIM
On 13th May 2024, Amur announced the proposed reverse takeover, change of name to CRISM Pharmaceuticals and admission to AIM. The admission became effective when dealings in the Enlarged Share Capital commenced on AIM on 31st May 2024.
For further information, click here.
The Perivan shareholder communications team was delighted to work with SP Angel Corporate Finance who acted as Nominated Adviser and Broker on the 139-page admission document which was successfully produced and published on 13th May 2024.
Perivan is the market leader for producing AIM admission documents having produced over 70% all IPOs & New Issues so far in 2024. To view our recent work, click here.